Last reviewed · How we verify
thiostrepton
thiostrepton is a drug. It is currently FDA-approved.
At a glance
| Generic name | thiostrepton |
|---|---|
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- SAP enzyme elevation
- SGPT (ALT) enzyme elevation
- Polydipsia
- Polyuria
- Vomiting
- Diarrhea
- Bloody diarrhea
Serious adverse events
- Cushing's syndrome
- Hearing loss
- Temporary hearing loss
Key clinical trials
- Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thiostrepton CI brief — competitive landscape report
- thiostrepton updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about thiostrepton
What is thiostrepton?
thiostrepton is a pharmaceutical drug.
What development phase is thiostrepton in?
thiostrepton is FDA-approved (marketed).
What are the side effects of thiostrepton?
Common side effects of thiostrepton include SAP enzyme elevation, SGPT (ALT) enzyme elevation, Polydipsia, Polyuria, Vomiting, Diarrhea. Serious adverse events: Cushing's syndrome, Hearing loss, Temporary hearing loss.
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other